OPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older. The use of ...

If approved, Opzelura would provide an alternative to steroid drugs currently used to treat vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

If you’re under age 12, we don’t have any drug that is specifically indicated,” Dr. Lawrence F. Eichenfield said.

In addition, Opzelura ® (ruxolitinib) was approved for the treatment of vitiligo in July 2022 and is projected to have sales of >$600 million for that indication in 2030 (EvaluatePharma).

Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in ...

which is the first drug that can restore pigment in patients with nonsegmental vitiligo. The Ruxolitinib cream can be used by adults and children ages 12 and up for treatment. In a statement ...

researchers evaluated the efficacy and safety of once-daily upadacitinib for the treatment of nonsegmental vitiligo for 52 weeks. Read more. Safety data show ruxolitinib cream well tolerated in ...

today announced completion of enrollment in the Phase 2b trial evaluating VYN201 gel for the treatment of nonsegmental vitiligo. Top-line data from the 24-week vehicle-controlled treatment period ...

Patients were required to have nonsegmental vitiligo covering at least 5% of their bodies, excluding hands and feet. As described above, the oral treatments were given for 12 weeks, then ...

There is currently only one FDA-approved product for the treatment of vitiligo. Nonsegmental vitiligo is the most common type of vitiligo. About Repibresib Repibresib is a pan-bromodomain BET ...